ACADIA Pharmaceuticals Inc. (ACAD)
After hours:
- Benzinga
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
The FDA has approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older. Daybue is the first and only drug approved for treating Rett syndrome, a rare genetic neurological and developmental disorder that causes a progressive loss of motor skills and language. Rett syndrome primarily affects females. Rett syndrome is believed to affect 6,000 to 9,000 patients in the U.S., with a diagnosed population of appr
- MarketWatch
Acadia’s rare-disease drug to cost $575,000 to $595,000
Acadia Pharmaceuticals Inc. (ACAD) said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson. The Food and Drug Administration on Friday approved Daybue, the first therapy to treat Rett syndrome, a rare disease that has been diagnosed in 4,500 adults and children in the U.S. The company said it expects to have the drug available in the U.S. by the end of April.
- Business Wire
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
SAN DIEGO, March 11, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome.
